OBM Transplantation (ISSN 2577-5820) is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc., which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
The journal publishes all types of articles in English. There is no restriction on the length of the papers. We encourage authors to be concise but present their results in as much detail as necessary, as reviewers are expected to emphasize scientific rigor and reproducibility.
Publication Speed (median values for papers published in 2023): Submission to First Decision: 6.7 weeks; Submission to Acceptance: 14.4 weeks; Acceptance to Publication: 6 days (1-2 days of FREE language polishing included)
Special Issue
Graft-versus-Host Disease
Submission Deadline:
September 15, 2020 (Open)
Submit Now
Guest Editor
Yvonne A. Efebera,
MD
Associate Professor, Blood and Marrow Transplantation Program, Ohio State University, Columbus, Ohio, USA
Website | E-Mail
Research Interests: Multiple myeloma; graft vs host disease; paraproteinemias; amyloidosis; necrobiotic xanthogranuloma; blood and marrow transplantation
About This Topic
Allogeneic hematopoietic stem cell transplant (alloHSCT) is a curative treatment for many hematologic malignancies. Unfortunately, about 30-50% of all recipients undergoing alloHSCT develop acute and chronic graft-versus-host-disease (aGVHD), which is associated with high morbidity and mortality [1, 2]. The pathophysiology of aGVHD is complex but involves the activation of host antigen presenting cells (APCs) by recipient conditioning which in turn activate transplanted donor T lymphocytes that expand and differentiate into effector cells that mediate cytotoxicity against recipient tissues through Fas-Fas ligand interactions, perforin-granzyme B, and cytokine production [2, 3, 4, 5]. When severe, aGVHD carries a poor prognosis, with only 25% long term survival for grade III and 5% for grade IV [6]. Major contributing factors to severity of GVHD include HLA mismatch, conditioning regimen intensity, age of donor and recipient, source of stem cell (Peripheral blood, bone marrow, cord blood), and donor type (related, unrelated, haploidentical). Strategies and clinical trials are ongoing to reduce the incidence of GVHD, and to improve on the survival outcome of patients with GVHD, including the assessment of microRNAs and use of biomarkers guided management. This issue welcomes submission in any areas that focuses on GVHD mitigation and management.
-
Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012; 12: 443-458.[CrossRef]
-
Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009; 373: 1550-1561.[CrossRef]
-
Socie G, Blazar BR. Acute graft-versus-host disease: From the bench to the bedside. Blood. 2009; 114: 4327-4336.[CrossRef]
-
Graubert TA, Russell JH, Ley TJ. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood. 1996; 87: 1232-1237.
-
Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med. 1987; 166: 1280-1289.
-
Deeg HJ. How I treat refractory acute GVHD. Blood. 2007; 109: 4119-4126.[CrossRef]
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (transplantation@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Publication
Abstract
Graft-versus host disease is one of the major causes of death in patients undergoing allogeneic hematopoietic stem cell transplantation. Major contributing factors to severity of graft-versus host disease include HLA mismatch, conditioning regimen intensity, age of donor and recipient, source of stem cell, and donor type. Strategies and clinic [...]
|
Abstract
Severe hypercholesterolemia is an uncommon complication of allogenic hematopoietic cell transplantation (HCT). Treatment options for hypercholesterolemia due to liver graft-versus-host disease (GVHD) are limited because many antilipidemic medications are known to worsen hepatic functions. We report our experience on a case of a 38-year-old [...]
|
Nidhi Sharma
and
